Related Experiment Video
Updated: May 15, 2025

06:08
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
Published on: March 21, 2025
108
Fast prostate MRI vs. conventional multiparametric prostate MRI: comparison and outcomes
Hamed Kordbacheh1,2, Gorica Ristic3, Elisabeth Heath1
1Karmanos Cancer Institute, Wayne State University, Detroit, USA.
Abdominal Radiology (New York)
|April 7, 2025
Summary
Fast prostate MRI (fpMRI) shows moderate to high concordance with conventional multiparametric MRI (mpMRI) for detecting prostate cancer. This pilot study suggests fpMRI may be a viable screening tool.
Area of Science:
- Radiology
- Oncology
- Medical Imaging
Background:
- Multiparametric prostate MRI (mpMRI) is a key tool for prostate cancer detection.
- Evaluating faster MRI protocols can improve efficiency and patient access.
Purpose of the Study:
- To compare the diagnostic concordance of a fast prostate MRI (fpMRI) protocol against the conventional mpMRI protocol.
- To assess the performance of fpMRI in detecting clinically significant prostate cancer.
Main Methods:
- Retrospective review of 100 men (ages 50-80) who underwent mpMRI.
- mpMRI exams categorized into PI-RADS 1-2 (Group A), PI-RADS 3 (Group B), and PI-RADS 4-5 (Group C).
- Two radiologists independently scored fpMRI, comparing results to mpMRI, PSA, and biopsy outcomes.
Main Results:
- Overall concordance between fpMRI reviewers and mpMRI was 0.69.
- Positive predictive values (PPV) for GS ≥ 7 in groups B/C combined were 62% (mpMRI), 67% (R1 fpMRI), and 72% (R2 fpMRI).
- Negative predictive values (NPV) for GS ≥ 7 in groups B/C combined were 100% (mpMRI), 100% (R1 fpMRI), and 92% (R2 fpMRI).
Conclusions:
- fpMRI demonstrated moderately high concordance, PPV, and very high NPV compared to mpMRI for PI-RADS 3-5 lesions.
- These findings support the potential of fpMRI as an efficient screening tool for prostate cancer.
- Further prospective studies are recommended to validate fpMRI's role in prostate cancer screening.

